Immunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia ...

Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...

Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...

The company plans to use results from its Phase III myasthenia gravis study to support its pipeline candidate IMVT-1402 over ...

The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.

Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and ...

Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...

Immunovant (IMVT) reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study ...

The company continues to focus on a next-generation drug while batoclimab’s testing in thyroid eye disease wraps up.

Beyond the results in MG and CIDP, we believe that our core thesis - that deeper IgG reduction, at the levels achieved by high dose batoclimab and high dose IMVT-1402, leads to improved clinical ...

Immunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia gravis (MG) and initial results from Period 1 of a mid-stage study of ...